Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393716 · ClinicalTrials.gov registry record · NA
Endurant Evo US Clinical Trial
A NA study, sponsored by Medtronic Cardiovascular.
- Terminated
- Registry status
- NA
- Development phase
- 139
- Enrollment target
NCT02393716: Clinical Trial NA study, sponsored by Medtronic Cardiovascular.
NCT02393716 is a NA study that was terminated before completion, run by Medtronic Cardiovascular. The registered enrollment target is 139 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02393716, a NA study, was terminated before completion, sponsored by Medtronic Cardiovascular.
- TERMINATED
- Registry status
- NA
- Development phase
- 139 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that the Endurant Evo Abdominal Aortic Aneurysm (AAA) stent graft system is safe and effective for endovascular treatment of infrarenal abdominal aortic or aortoiliac aneurysms.
Primary Outcome
The percentage of subjects experiencing a Major Adverse Event (MAE) within 30 days post-implantation. MAEs include the occurrence of any of the following events: * All-cause mortality * Bowel ischemia * Myocardial infarction * Paraplegia * Procedural blood loss ≥1000 cc * Renal failure * Respiratory failure * Stroke
Interventions
- DEVICE Endurant Evo AAA Stent Graft System
- PROCEDURE Endovascular aneurysm repair (EVAR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2015-04 |
| Est. Completion | 2021-06-25 |
| Phase | NA |
Why NCT02393716 stopped before completion
NCT02393716 is an interventional study that assigns participants to a tested intervention. The registered 139 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Endurant Evo AAA Stent Graft System is the first listed.
NCT02393716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02393716 about?
NCT02393716 is a clinical study titled "Endurant Evo US Clinical Trial". The purpose of this study is to demonstrate that the Endurant Evo Abdominal Aortic Aneurysm (AAA) stent graft system is safe and effective for endovascular treatment of infrarenal abdominal aortic or aortoiliac aneurysms.
What is the current status of trial NCT02393716?
This trial is currently terminated. It is a NA study. The enrollment target is 139 participants. The study started on 2015-04. Estimated completion is 2021-06-25.
What interventions are being tested in trial NCT02393716?
The interventions under investigation include: Endurant Evo AAA Stent Graft System (DEVICE), Endovascular aneurysm repair (EVAR) (PROCEDURE).
Who is sponsoring clinical trial NCT02393716?
This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02393716's enrollment target sits among peer trials
139 720th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645380 · 139 participants · Phase 2
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- NCT06239272 · 139 participants · Phase 1
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- NCT06252220 · 139 participants · Phase 1
First in Human Study in Subjects With Obesity, But Otherwise Healthy
- NCT06537128 · 139 participants · NA
Internet-delivered Cognitive-Behavioral Therapy for Adolescents With Autism and Anxiety
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia